Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 1/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.34 |
| ▸ | EP300 | Q09472 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL94996 | 0.88 | IGF1R (1.00) | IGF1RALDH1A1KMT2APOLBLMNA | |
| SCHEMBL13919302 | 0.88 | IGF1R (0.76) | IGF1RALDH1A1KMT2APOLBRAB9A | |
| SCHEMBL4208158 | 0.88 | IGF1R (0.76) | IGF1RALDH1A1KMT2APOLBLMNA | |
| SCHEMBL4498917 | 0.83 | IGF1R (0.54) | IGF1RALDH1A1KMT2APOLBNPSR1 | |
| SCHEMBL14195910 | 0.82 | IGF1R (0.80) | IGF1RALDH1A1KMT2APOLBHPGD | |
| SCHEMBL14142077 | 0.82 | IGF1R (0.56) | IGF1RALDH1A1KMT2APOLBNPSR1 | |
| SCHEMBL13865136 | 0.82 | IGF1R (0.71) | IGF1RALDH1A1KMT2APOLBRAB9A | |
| SCHEMBL4205764 | 0.81 | IGF1R (0.66) | IGF1RALDH1A1KMT2APOLB | |
| SCHEMBL13933186 | 0.80 | IGF1R (0.51) | IGF1RALDH1A1KMT2APOLBNPSR1 | |
| SCHEMBL4205450 | 0.80 | IGF1R (0.71) | IGF1RALDH1A1KMT2APOLBNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504429-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2009-03-17 | — | — | US | disclosed |
| EP-1651599-A4 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2008-09-24 | — | — | EP | disclosed |
| US-20060189577-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2006-08-24 | — | — | US | disclosed |
| EP-1651599-A1 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005009957-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189577-A1 | Tyrosine kinase inhibitors | ABL1, RET, ERBB2 | IGF1R 102/4885ALDH1A1 2755/4885KMT2A 1302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.